Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Procedures for the Clinical Laboratory Improvement Amendments of 1988 Categorization, 23781-23782 [2010-10358]
Download as PDF
Federal Register / Vol. 75, No. 85 / Tuesday, May 4, 2010 / Notices
Dated: April 28, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–10361 Filed 5–3–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0199]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Administrative
Procedures for the Clinical Laboratory
Improvement Amendments of 1988
Categorization
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
administrative procedures for the
Clinical Laboratory Improvement
Amendments of 1988 (CLIA)
categorization.
DATES: Submit written or electronic
comments on the collection of
information by July 6, 2010.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information
including each proposed extension an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
23781
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Administrative Procedures for CLIA
Categorization—42 CFR 493.17 (OMB
Control Number 0910–0607–Extension)
A guidance document entitled
‘‘Guidance for Administrative
Procedures for CLIA Categorization’’ was
released on May 7, 2008. The document
describes procedures FDA will use to
assign the complexity category to a
device. Typically, FDA assigns
complexity categorizations to devices at
the time of clearance or approval of the
device. In this way, no additional
burden is incurred by the manufacturer
since the labeling (including operating
instructions) is included in the 510(k) or
PMA. In some cases, however, a
manufacturer may request CLIA
categorization even if FDA is not
simultaneously reviewing a 510(k) or
PMA. One example is when a
manufacturer requests that FDA assign
CLIA categorization to a previously
cleared device that has changed names
since the original CLIA categorization.
Another example is when a device is
exempt from premarket review. In such
cases, the guidance recommends that
manufacturers provide FDA with a copy
of the package insert for the device and
a cover letter indicating why the
manufacturer is requesting a
categorization (e.g. name change,
exempt from 510(k) review). The
guidance recommends that in the
correspondence to FDA the
manufacturer should identify the
product code and classification as well
as reference to the original 510(k) when
this is available.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
CFR
Section
No. of
Respondents
42 CFR 493.17
mstockstill on DSKH9S0YB1PROD with NOTICES
1 There
Annual Frequency
per Response
60
Total Annual
Responses
15
Hours per
Responses
900
Total Hours
1 hr
900 hr
Total Operating &
Maintenance Costs
$46,800
are no capital costs associated with this collection of information.
The number of respondents is
approximately 60. On average, each
respondent will request categorizations
(independent of a 510(k) or PMA) 15
times per year. The cost, not including
personnel, is estimated at $52 per hour
(52 x 900) totaling $46,800. This
includes the cost of copying and mailing
VerDate Mar<15>2010
18:58 May 03, 2010
Jkt 220001
copies of package inserts and a cover
letter, which includes a statement of the
reason for the request and reference to
the original 510(k) numbers, including
regulation numbers and product codes.
The burden hours are based on FDA
familiarity with the types of
documentation typically included in a
PO 00000
Frm 00118
Fmt 4703
Sfmt 4703
sponsor’s categorization requests, and
costs for basic office supplies (e.g.
paper). The costs have been updated
based on the Bureau of Labor Statistics
estimates of inflation.
E:\FR\FM\04MYN1.SGM
04MYN1
23782
Federal Register / Vol. 75, No. 85 / Tuesday, May 4, 2010 / Notices
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 28, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–10358 Filed 5–3–10; 8:45 am]
Dated: April 27, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2010–10268 Filed 5–3–10; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSKH9S0YB1PROD with NOTICES
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Food and Drug Administration
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Bariatric Surgery
and Kidney Function.
Date: June 8, 2010.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: D.G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Collaborative
Interdisciplinary.
Date: June 11, 2010.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: D.G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
VerDate Mar<15>2010
18:58 May 03, 2010
Jkt 220001
[Docket No. FDA–2010–N–0001]
Drug Safety and Risk Management
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Drug Safety and
Risk Management Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 14, 2010, from 8 a.m.
to 5 p.m.
Location: The Marriott Inn and
Conference Center, University of
Maryland and University College
(UMUC), The Ballrooms, 3501
University Blvd. East, Adelphi, MD. The
conference center telephone number is
301–985–7300.
Contact Person: Elaine Ferguson, email: elaine.ferguson@fda.hhs.gov
(contact information through June 8,
2010, Elaine Ferguson c/o Melanie
Whelan, Food and Drug Administration,
10903 New Hampshire Ave., WO51–
6100, Silver Spring, MD 20993–0002,
telephone: 301–827–7001, FAX: 301–
847–8742), (contact information
beginning June 9, 2010: Elaine Ferguson
c/o Christine Shipe, Food and Drug
Administration, 10903 New Hampshire
Ave., WO31–2419, Silver Spring, MD
20993–0002, telephone: 301–0796–
9001, FAX: 301–847–8532), or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512535. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On September 14, 2010, the
committee will discuss the abuse
potential of the drug dextromethorphan
and the public health benefits and risks
of dextromethorphan use as a cough
suppressant in prescription and
nonprescription drug products. The
Department of Health and Human
Services received a request from the
Drug Enforcement Administration for a
scientific and medical evaluation and
scheduling recommendation for
dextromethorphan in response to the
increased incidence of abuse, especially
among adolescents.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 30, 2010.
Oral presentations from the public will
be scheduled between approximately 1
p.m. to 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 20, 2010. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 23, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
E:\FR\FM\04MYN1.SGM
04MYN1
Agencies
[Federal Register Volume 75, Number 85 (Tuesday, May 4, 2010)]
[Notices]
[Pages 23781-23782]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-10358]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0199]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Administrative Procedures for the Clinical Laboratory
Improvement Amendments of 1988 Categorization
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on administrative procedures for
the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
categorization.
DATES: Submit written or electronic comments on the collection of
information by July 6, 2010.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information including
each proposed extension an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Administrative Procedures for CLIA Categorization--42 CFR 493.17 (OMB
Control Number 0910-0607-Extension)
A guidance document entitled ``Guidance for Administrative
Procedures for CLIA Categorization'' was released on May 7, 2008. The
document describes procedures FDA will use to assign the complexity
category to a device. Typically, FDA assigns complexity categorizations
to devices at the time of clearance or approval of the device. In this
way, no additional burden is incurred by the manufacturer since the
labeling (including operating instructions) is included in the 510(k)
or PMA. In some cases, however, a manufacturer may request CLIA
categorization even if FDA is not simultaneously reviewing a 510(k) or
PMA. One example is when a manufacturer requests that FDA assign CLIA
categorization to a previously cleared device that has changed names
since the original CLIA categorization. Another example is when a
device is exempt from premarket review. In such cases, the guidance
recommends that manufacturers provide FDA with a copy of the package
insert for the device and a cover letter indicating why the
manufacturer is requesting a categorization (e.g. name change, exempt
from 510(k) review). The guidance recommends that in the correspondence
to FDA the manufacturer should identify the product code and
classification as well as reference to the original 510(k) when this is
available.
FDA estimates the burden of this collection of information as
follows:
TABLE 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per Total Operating &
CFR Section Respondents per Response Responses Responses Total Hours Maintenance Costs
--------------------------------------------------------------------------------------------------------------------------------------------------------
42 CFR 493.17 60 15 900 1 hr 900 hr $46,800
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs associated with this collection of information.
The number of respondents is approximately 60. On average, each
respondent will request categorizations (independent of a 510(k) or
PMA) 15 times per year. The cost, not including personnel, is estimated
at $52 per hour (52 x 900) totaling $46,800. This includes the cost of
copying and mailing copies of package inserts and a cover letter, which
includes a statement of the reason for the request and reference to the
original 510(k) numbers, including regulation numbers and product
codes. The burden hours are based on FDA familiarity with the types of
documentation typically included in a sponsor's categorization
requests, and costs for basic office supplies (e.g. paper). The costs
have been updated based on the Bureau of Labor Statistics estimates of
inflation.
[[Page 23782]]
Dated: April 28, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-10358 Filed 5-3-10; 8:45 am]
BILLING CODE 4160-01-S